Razelle Kurzrock

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:2458-65. 2010
  2. pmc BRAF mutations in advanced cancers: clinical characteristics and outcomes
    Hazem El-Osta
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e25806. 2011
  3. pmc R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis
    Helen J Huang
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e26060. 2011
  4. doi Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6144-51. 2012
  5. doi Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways
    Laura S Angelo
    Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 10:2094-103. 2011
  6. doi Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 11:308-16. 2012
  7. ncbi Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
    Razelle Kurzrock
    Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:4527-34. 2003
  8. ncbi Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance
    Razelle Kurzrock
    Division of Cancer Medicine, The University of Texas, M D Anderson Cancver Center, Houston, Texas 77230 1402, USA
    Leuk Lymphoma 47:1651-64. 2006
  9. doi Project Zero Delay: a process for accelerating the activation of cancer clinical trials
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, M D Anderson Cancer Center, Unit 455, PO Box 301402 Houston, TX 77030, USA
    J Clin Oncol 27:4433-40. 2009
  10. ncbi Purine analogues in advanced T-cell lymphoid malignancies
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:S27-34. 2006

Research Grants

  1. Farnesyltransferase Inhibitor Therapy for Myelodysplasia
    Razelle Kurzrock; Fiscal Year: 2002
  2. Exploratory Trial of Curcumin in Pancreatic Cancer
    Razelle Kurzrock; Fiscal Year: 2005
  3. Phase I Studies of Targeted Anti-Cancer Therapies
    Razelle Kurzrock; Fiscal Year: 2007

Detail Information

Publications157 found, 100 shown here

  1. doi A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:2458-65. 2010
    ..Subsequent cohorts were dosed at 3 and then 9 mg/kg. An additional 12 patients received 9 mg/kg R1507 qW. Patients remained on the study until the development of a dose-limiting toxicity or progressive disease...
  2. pmc BRAF mutations in advanced cancers: clinical characteristics and outcomes
    Hazem El-Osta
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e25806. 2011
    ..We examined the clinical characteristics and outcomes of patients with mutant (mut) BRAF advanced cancer referred to phase 1 clinic...
  3. pmc R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis
    Helen J Huang
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e26060. 2011
    ..We conclude that antibodies and siRNA to IGF-1R, as well as siRNA to EWS/FLI-1, act via intersecting IGF/IGF-1R signals that suppress a common point in this pathway, namely the phosphorylation of Akt...
  4. doi Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6144-51. 2012
    ..In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients with advanced solid tumors...
  5. doi Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways
    Laura S Angelo
    Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 10:2094-103. 2011
    ..The combination of curcumin and an hsp inhibitor synergistically suppressed schwannoma cell growth. Our results provide a rationale for combining curcumin and KNK437 in the treatment of NF2...
  6. doi Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 11:308-16. 2012
    ..GRN1005 was well tolerated and showed activity in heavily pretreated patients with advanced solid tumors, including those who had brain metastases and/or failed prior taxane therapy...
  7. ncbi Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
    Razelle Kurzrock
    Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:4527-34. 2003
    ..09). We conclude that, at doses that are well tolerated, R115777 markedly inhibits the FTase target and has antitumor activity in MDS...
  8. ncbi Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance
    Razelle Kurzrock
    Division of Cancer Medicine, The University of Texas, M D Anderson Cancver Center, Houston, Texas 77230 1402, USA
    Leuk Lymphoma 47:1651-64. 2006
    ....
  9. doi Project Zero Delay: a process for accelerating the activation of cancer clinical trials
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, M D Anderson Cancer Center, Unit 455, PO Box 301402 Houston, TX 77030, USA
    J Clin Oncol 27:4433-40. 2009
    ..Eliminating administrative delays can accelerate the evaluation of new drugs without compromising patient safety or the quality of clinical research...
  10. ncbi Purine analogues in advanced T-cell lymphoid malignancies
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:S27-34. 2006
    ..Future studies of purine analogues should evaluate patients who are less heavily pretreated and combination therapy with other agents such as alemtuzumab should be investigated in order to prolong the duration of disease remission...
  11. ncbi I have good news! You have leukemia
    Razelle Kurzrock
    Phase I Program, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Dermatol 25:350-2. 2007
  12. ncbi Cutaneous castleman's disease responds to anti interleukin-6 treatment
    Bilal Ahmed
    Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, TX 77030, USA
    Mol Cancer Ther 6:2386-90. 2007
    ..Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses...
  13. ncbi Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  14. ncbi Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:1361-7. 2005
    ....
  15. pmc Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
    Razelle Kurzrock
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:2660-6. 2011
    ..Early observations of clinical benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article...
  16. ncbi Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics
    Razelle Kurzrock
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, Texas 77030, USA
    Ann Intern Med 138:819-30. 2003
    ..This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach...
  17. doi Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome
    Razelle Kurzrock
    Phase I Program, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Cancer Res 14:509-14. 2008
    ..To determine the safety and describe the antitumor activity of tipifarnib in patients with myelodysplastic syndrome (MDS) using an alternate-week schedule...
  18. ncbi Studies in target-based treatment
    Razelle Kurzrock
    Phase I Program, Division of Cancer Medicine, Unit 422, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 6:2385. 2007
  19. ncbi Therapy of T cell lymphomas with pentostatin
    R Kurzrock
    Department of Bioimmunotherapy, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Ann N Y Acad Sci 941:200-5. 2001
    ..These observations suggest that further exploration of this agent, in combination with other drugs active in T cell lymphomas, is warranted in this group of diseases...
  20. ncbi Studies in target-based treatment
    Razelle Kurzrock
    Phase I Program, Division of Cancer Medicine, Unit 422, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 6:1477. 2007
    ....
  21. ncbi Cytokine deregulation in cancer
    R Kurzrock
    Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Biomed Pharmacother 55:543-7. 2001
    ..The molecular mechanisms underlying cytokine deregulation are now being investigated, with preliminary data suggesting heterogeneous genetic driving forces, including oncogene aberrations and viral infection...
  22. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  23. pmc Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  24. pmc Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Texas, USA
    Oncotarget 4:772-84. 2013
    ..We therefore investigated the outcome of EGFR inhibitor-based combination regimens in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a Phase I Clinic...
  25. doi Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity
    John Moroney
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:5796-805. 2012
    ..Preclinical data suggest that combining the mTOR/hypoxia-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to anthracyclines...
  26. doi Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  27. ncbi Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model
    Jing Gong
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2239-47. 2009
    ..This type of agent merits investigation in the clinic to determine if it can predict patient responses to kinase inhibitors based on phosphokinase imaging...
  28. pmc Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 66:1087-93. 2010
    ..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement...
  29. ncbi Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1692-7. 2003
    ..R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777...
  30. pmc Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1192-200. 2013
    ..Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells...
  31. doi Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6373-83. 2012
    ..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations...
  32. ncbi Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 379:1893-901. 2012
    ..We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases...
  33. doi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  34. pmc The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street Unit 1340, Houston, TX 77030 4009, USA
    Cancer Epidemiol Biomarkers Prev 17:3262-7. 2008
    ....
  35. pmc Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases
    Luis H Camacho
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Colorectal Cancer 9:311-4. 2010
    ....
  36. pmc Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Pain Symptom Manage 38:894-902. 2009
    ..23, 95% CI=1.4, 4.7) for severe pain relative to the AA genotypes. We provide preliminary evidence of the role of IL-8 in the severity of pain in pancreatic cancer patients. Additional studies are needed in larger cohorts of patients...
  37. doi A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 31:918-26. 2013
    ..Dasatinib has been shown preclinically to overcome resistance to gemcitabine. We evaluated the safety and biological activity of the combination of dasatinib and gemcitabine in patients with advanced solid tumors...
  38. pmc Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies
    David S Hong
    Division of Cancer Medicine, Department of Investigational Therapeutics Phase 1 Program, Unit 455, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 15:7061-8. 2009
    ....
  39. ncbi Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
    David S Hong
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Dermatol 144:779-82. 2008
    ....
  40. pmc Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy
    Henrique A Parsons
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nutr Cancer 64:206-17. 2012
    ..171). In conclusion, body composition was not significantly associated with toxicities or survival in our small sample...
  41. pmc Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience
    Christos Vaklavas
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 117:77-85. 2011
    ..The purpose of this study was to report the presenting characteristics and outcomes of patients with locally advanced or metastatic pancreatic cancer treated on phase 1 clinical trials at a single institution...
  42. pmc A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:4086-94. 2010
    ..The authors of this report conducted a phase 1 study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases...
  43. pmc Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:997-1005. 2011
    ..We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins...
  44. doi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS...
  45. doi Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy
    David S Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Cancer Res Clin Oncol 139:963-70. 2013
    ..The purpose of this study was to identify factors related to patients' willingness to provide study-related tumor biopsies in phase 1 clinical trials of molecularly targeted therapy...
  46. doi Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
    ..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials...
  47. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  48. doi A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer
    Stacy Moulder
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Unit 1354, 1155 Pressler Street, Houston, TX 77030, USA
    Invest New Drugs 28:634-40. 2010
    ..This trial was designed to establish the maximum tolerated dose (MTD) of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC)...
  49. pmc Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:247-53. 2011
    ..The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement...
  50. pmc A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
    John W Moroney
    Department of Gynecology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6840-6. 2011
    ..We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates...
  51. ncbi MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston TX, USA Electronic address
    Lancet Oncol 15:656-66. 2014
    ..We aimed to assess the safety and tolerability of MABp1 for interleukin-1α blockade in a refractory cancer population...
  52. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  53. ncbi Phase II study of alemtuzumab in chronic lymphoproliferative disorders
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:773-8. 2003
    ..Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders...
  54. pmc Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, U T MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:118-27. 2013
    ..Preclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models...
  55. pmc PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration...
  56. doi Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 71:389-97. 2013
    ..Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients...
  57. doi A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas
    David S Hong
    Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:3396-406. 2012
    ....
  58. ncbi Salirasib in the treatment of pancreatic cancer
    Ernesto Bustinza-Linares
    Department of Investigational Cancer Therapeutics, The Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Future Oncol 6:885-91. 2010
    ..7 months. Future studies will determine whether salirasib adds to the anti-tumor activity of drugs approved by the US FDA for pancreatic cancer...
  59. pmc Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 126:47-53. 2012
    ..On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer...
  60. ncbi Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer
    Lan Li
    Phase I Program, Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 6:1276-82. 2007
    ..We are currently developing liposomal curcumin for introduction into the clinical setting...
  61. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  62. pmc Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib
    Gerald S Falchook
    Division of Cancer Medicine, Departmentof Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston, TX 77030, USA
    JAMA Dermatol 149:322-6. 2013
    ..We report what we believe to be the first case in which Merkel cell polyomavirus (MCPyV) and human papillomavirus subtype 17 (HPV-17) were associated with cutaneous SCC that developed during treatment with the BRAF inhibitor dabrafenib...
  63. doi A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
    David S Hong
    MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 18:4173-82. 2012
    ..The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in patients with incurable cancers...
  64. doi Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Biostatistics, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2922-9. 2012
    ....
  65. pmc Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2625-31. 2012
    ..Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R)...
  66. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  67. doi Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Breast Cancer 10:46-51. 2010
    ..Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents...
  68. pmc Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009
    ..Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed...
  69. ncbi Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
    Jorge Cortes
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:2805-12. 2005
    ..To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS)...
  70. pmc Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, Texas 77030, USA
    Mol Cancer Ther 11:2541-6. 2012
    ....
  71. pmc Molecular imaging of Bcr-Abl phosphokinase in a xenograft model
    Ji Yuan Wu
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Unit 455, P O Box 301402, Houston, TX 77030, USA
    Mol Cancer Ther 8:703-10. 2009
    ..This technique may therefore be useful in the clinic to detect the presence of phosphokinase activity and for early prediction of response...
  72. ncbi Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:574-80. 2004
    ..The aim of the current study was to assess the toxicity, safety, and efficacy of IFN-alpha combined with isotretinoin in patients with advanced, refractory lymphoid malignancies...
  73. ncbi Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses
    Hillary H Wu
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2410-9. 2003
    ..Because of the paucity of effective therapies for patients with chronic bone marrow failure states, the authors studied the biologic activity of sequential IL-3/GM-CSF in such patients...
  74. pmc Reproducibility of CT perfusion parameters in liver tumors and normal liver
    Chaan S Ng
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1400 Pressler St, Unit 1473, Houston, TX 77030 4009, USA
    Radiology 260:762-70. 2011
    ..To assess the reproducibility of computed tomographic (CT) perfusion measurements in liver tumors and normal liver and effects of motion and data acquisition time on parameters...
  75. pmc Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience
    Hazem El-Osta
    Department of Investigational Therapeutics, Phase 1 Program Unit 455, Division of Cancer Medicine, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 16:1292-8. 2011
    ..Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies...
  76. pmc Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers
    Fadi Braiteh
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine and Quantitative Sciences, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 14:6296-301. 2008
    ..On the basis of this evidence, we conducted a phase I study of the combination of 5-AZA and valproic acid in patients with advanced cancers...
  77. ncbi Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein ki
    Doris R Siwak
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 104:879-90. 2005
    ....
  78. pmc Effect of sampling frequency on perfusion values in perfusion CT of lung tumors
    Chaan S Ng
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Unit 1473, 1400 Pressler St, Houston, TX 77030 4009, USA
    AJR Am J Roentgenol 200:W155-62. 2013
    ..The purpose of this study was to assess as a potential means of limiting radiation exposure the effect on perfusion CT values of increasing sampling intervals in lung perfusion CT acquisition...
  79. doi Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
    Apostolia Maria Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Chemother Pharmacol 65:235-41. 2010
    ..This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling...
  80. pmc Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver
    Chaan S Ng
    Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Comput Assist Tomogr 36:388-93. 2012
    ..To assess the impact on absolute values and reproducibility of adding portal venous (PV) to arterial input functions in computed tomographic perfusion (CTp) evaluations of liver tumors and normal liver...
  81. doi Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
    ..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis...
  82. doi Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1300-7. 2011
    ..HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases...
  83. ncbi Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics a Phase 1 Program, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 115:1091-9. 2009
    ....
  84. pmc Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study
    David Hui
    Department of Palliative Care and Rehabilitation Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4402-9. 2010
    ..In the current study, the timing of referral and symptom burden between patients referred to palliative care by phase 1 oncologists and those referred by non-phase 1 oncologists were compared...
  85. pmc Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse
    Rajul K Jain
    Department of Investigational Cancer Therapeutics, Phase I Program, MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 16:1289-97. 2010
    ..However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies...
  86. pmc PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  87. ncbi Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:3547-52. 2011
    ..This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy...
  88. doi Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
    Putao Cen
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 58:382-6. 2008
    ..29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer...
  89. ncbi Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 51:200-4. 2004
    ..Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL)...
  90. pmc Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience
    Apostolia Maria Tsimberidou
    Investigational Cancer Therapeutics and Quantitative Sciences Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 17:4110-8. 2011
    ..Patients with brain metastases are often excluded from clinical trials, but it is unclear whether they pose an enhanced risk...
  91. ncbi Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 100:342-9. 2004
    ..The goal of the current study was to assess the toxicity, safety, and efficacy of pentostatin in patients with T-cell lymphoid malignancies...
  92. doi Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
    Apostolia Maria Tsimberidou
    Phase 1 Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1507-16. 2011
    ..Midazolam and omeprazole are primarily metabolized by CYP3A4 and CYP2C19, respectively. We evaluated the inhibitory effects of patupilone on the CYP3A4/CYP2C19 pathways...
  93. doi Phase II trial of curcumin in patients with advanced pancreatic cancer
    Navneet Dhillon
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:4491-9. 2008
    ..We evaluated the clinical biological effects of curcumin (diferuloylmethane), a plant-derived dietary ingredient with potent nuclear factor-kappaB (NF-kappaB) and tumor inhibitory properties, against advanced pancreatic cancer...
  94. doi Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides
    Grace Sun
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 60:231-5. 2009
    ..Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is most often seen in middle-aged to elderly men...
  95. doi A first-in-human study of conatumumab in adult patients with advanced solid tumors
    Roy S Herbst
    Head and Neck Head and Neck Medical Oncology and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:5883-91. 2010
    ..To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors...
  96. doi Chemotherapy resistance and retreatment: a dogma revisited
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston
    Clin Colorectal Cancer 9:E1-4. 2010
    ..Herein, we report several cases in which retreatment with drugs that had failed earlier in the disease trajectory caused renewed tumor regression. The possible biologic underpinnings that might explain this phenomenon are discussed...
  97. ncbi The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines
    Mi Ae Lyu
    Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0044, Houston, TX 77030, USA
    Biochem Pharmacol 75:836-46. 2008
    ..Delivery of the cytokine TNF to HER-2/neu expressing pancreatic tumor cells, which are inherently resistant to TNF using scFv23/TNF may be an effective therapy for pancreatic cancer especially when utilized in combination with 5-FU...
  98. doi Development of curcumin as an epigenetic agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4670-6. 2010
    ..The development of curcumin as an epigenetic agent warrants further preclinical and clinical studies to explore its diversity and efficacy in cancer treatment and in combination with other anticancer agents...
  99. ncbi Farnesyltransferase inhibitors
    Razelle Kurzrock
    The University of Texas M D Anderson Cancer Center, TX, USA
    Clin Adv Hematol Oncol 3:161-2. 2005
  100. ncbi Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience
    Sushma Vemulapalli
    Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Am J Hematol 84:408-13. 2009
    ..A prognostic score that can be used to predict time to development of and frequency of VTE is proposed. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  101. pmc Molecular epidemiology, cancer-related symptoms, and cytokines pathway
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Lancet Oncol 9:777-85. 2008
    ..Likewise, they could identify subgroups who might benefit most from symptom intervention, and contribute to developing personalized and more effective therapies for persistent symptoms...

Research Grants5

  1. Farnesyltransferase Inhibitor Therapy for Myelodysplasia
    Razelle Kurzrock; Fiscal Year: 2002
    ....
  2. Exploratory Trial of Curcumin in Pancreatic Cancer
    Razelle Kurzrock; Fiscal Year: 2005
    ..These studies should provide the foundation for the development of curcumin as an anticancer agent and may lead to a novel approach to the management of pancreatic cancer. ..
  3. Phase I Studies of Targeted Anti-Cancer Therapies
    Razelle Kurzrock; Fiscal Year: 2007
    ....